Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells

Oncogenic receptor tyrosine kinases including anaplastic lymphoma kinase (ALK) are implicated in numerous solid and hematologic cancers. ALK mutations are reported in an estimated 9% of neuroblastoma and recent reports indicate that the percentage of ALK-positive cases increases in the relapsed pati...

Full description

Bibliographic Details
Main Authors: Muhammad Wasi Alam, Marcus Borenäs, Dan E. Lind, Diana Cervantes-Madrid, Ganesh Umapathy, Ruth H. Palmer, Bengt Hallberg
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-07-01
Series:Frontiers in Oncology
Subjects:
neuroblastoma
alectinib
anaplastic lymphoma kinase (ALK)
resistant mutations
xenograft
crizotinib
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00579/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00579/full

Similar Items